Navigation Links
Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
Date:10/24/2008

EAST BRUNSWICK, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the third quarter 2008 following the close of the market on Wednesday, November 5, 2008.

Christopher Clement, President and Chief Executive Officer and Brian Hayden, Senior Vice President and Chief Financial Officer will host an investment community conference call beginning at 10:00 a.m. Eastern Time on November 6, 2008 to discuss these results and to answer questions.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of Savient Pharmaceuticals' web site at http://www.savient.com. To listen to the live call, please go to the web site fifteen minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on the web site. A telephone replay will be available from 12:00 p.m. Eastern Time on November 6, 2008 through 11:59 p.m. Eastern Time on November 20, 2008 by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering conference ID number 67897749.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, Puricase(R) (pegloticase) for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... June 17, 2013 zuChem Inc., ... health and nutrition, announced today that the United ... 2 patents - US 8,367,346 entitled “Methods for ... entitled "Process for producing D-Mannitol." These two patents ... of natural food sweetener products from abundant, renewable ...
(Date:6/17/2013)... June 17, 2013 Cedars-Sinai Medical Center, ... the country, recovered more than $300 million by ... of OnBase, Hyland Software,s enterprise content management ... provide a common revenue cycle management platform to ... were in place for both hospital and physician ...
(Date:6/17/2013)... COLUMBUS, Ohio , June 17, 2013 /PRNewswire/ ... has raised an additional $2.5 million from Radius ... $11.5 million. The Series B originally raised $9 ... with participation by existing investor, Charter Life Sciences. ... system is the first and only product that ...
(Date:6/17/2013)... , June 17, 2013 /PRNewswire-iReach/ -- The Greater ... Riedford , President/Founder of Riedford Management, Inc. to its Board ... a member of the Chamber,s Board of Advisors," said ... is one of the most prestigious positions to hold in ... experience our new board members will contribute." The ...
Breaking Biology Technology:zuChem Receives Two Polyol Patents 2Cedars-Sinai Medical Center Recovers More Than $300 million in AR with Hyland Software's OnBase 2Cedars-Sinai Medical Center Recovers More Than $300 million in AR with Hyland Software's OnBase 3Minimally Invasive Devices Adds $2.5 Million to its Series B 2Raleigh Chamber Names Bob Riedford to Board of Advisors 2
... Graduate Institute,(KGI) in collaboration with City of Hope, ... launch of its new Certificate in Bioscience,Management program ... funding to allow a limited number of City ... scholarships that will cover tuition., "KGI has ...
... ALTO, Calif., Aug. 14 CV Therapeutics,Inc. (Nasdaq: ... from the,European Medicines Agency (EMEA) for the brand name ... announced that the EMEA had granted,marketing authorization for ranolazine ... brand name Latixa., "Securing approval for the Ranexa ...
... Eric P. Loukas, Industry Veteran, Named as CEO ... Co-Founder, Named as President and COO, ALTAMONTE SPRINGS, ... specialty biotechnology company focused on,in-licensing and commercialization of niche ... as Chief Executive Officer,effective August 12, 2008. Current President, ...
Cached Biology Technology:City of Hope Helps KGI Launch New Management Training Program for Scientists 2City of Hope Helps KGI Launch New Management Training Program for Scientists 3CV Therapeutics Receives European Approval for the Brand Name Ranexa(R) 2Milestone Biosciences, LLC Further Strengthens Executive Management Team 2
(Date:6/17/2013)... by fungi, bacteria, and algae, is a common component ... used in the medical field it,s approved by ... fluids and used during surgery as a substance that ... other drugs. , Now Profs. Ehud Gazit and Daniel ... and Biotechnology and the Sagol School of Neuroscience, along ...
(Date:6/17/2013)... will be the topics under discussion during the ... the third consecutive year, this will be a ... experiences among members of Academy, Business, Educators, Entrepreneurs, ... speakers: Elisa Martn Garijo (IBM South Europe), Chris ... Mary O,Donovan (Hovione), among others. E3 Forum - ...
(Date:6/17/2013)... available in French . ... older mice with Alzheimer,s disease can be reversed with treatment. ... Hospital - The Neuro, at McGill University and at Universit ... receptor in the brain of mice with advanced Alzheimer,s disease ... the Journal of Neuroinflammation in May, also suggest ...
Breaking Biology News(10 mins):Artificial sweetener a potential treatment for Parkinson's disease 2'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2
... Gasterosteus aculeatus , is one of the most thoroughly ... particularly useful model for understanding variation in physiology, behavior, ... in the wild. On biological levels from molecular ... with the population level, it has proven far more ...
... a little gooey, but it,s not turning mums, brains into ... University. The study conducted by the Centre for ... fears mothers may have that pregnancy affects their cognitive functions, ... findings have been released as part of Mental Health Week, ...
... ability to respond? Biodiversity in a Warmer World, published ... Science , illustrates that cross-disciplinary research fostered by ... this urgent debate. , As an extremely diverse region ... the most to lose as a result of global ...
Cached Biology News:Fitness in a changing world 2Fitness in a changing world 3Pregnancy not turning minds to mush: Study 2Smithsonian perspective: Biodiversity in a warmer world 2
... Select Tissue Arrays are intended for laboratory ... were fixed in neutral buffered formalin and ... diagnosis was performed by certified pathologists. ... blocks and relocated into a new recipient ...
... analysis standard is a lyophilized mixture ... alcohol; molecular weights range from 152 ... for use with the Aminex HPX-87C ... for column testing or semiquantitative determination. ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
... The kit was tested on rat tissue ... a yeast ( S. cerevisae ) extract. It ... rat tissues and cell lines. Application: A simple ... sub-cellular fractions based on the detection of the ...
Biology Products: